5-YEAR SURVIVAL OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS
Keywords:
Triple negative breast cancer, survival, mortality, immuhistochemistry, breast cancer.Abstract
This study is a 5 year survival analysis in breast cancer triple negative patients, from 2006 to 2012, at the San Juan de Dios Hospital, San José, Costa Rica. Breast cancer is a heterogeneous pathology and it’s the main death cause in Costa Rican women. Breast cancer can be classified according to the expression of hormonal receptor (estrogen, progesterone) and HER-2, determined with immunohistochemical techniques. Breast carcinomas that result negative for these results are denominated triple negative carcinomas. Results show that 18% of the studied population (I.C. 95% 12.79-23.4) of breast carcinomas were triple negative, these represent more aggressive histological characteristics, worst prognosis, younger patients and a smaller survival rate compared to other types of breast carcinomas. Five year survival with this type of tumor was 60 months in 96.0% (IC 95% 74.8-99.4), 82.6% (IC 95% 69.3-90.6) for patients at stage II, and 87.5% (IC 95% 70.1-95.1) in patients at stage III. Only two patients had stage IV and didn’t reach a 60-month survival.
References
2. Corvalan, A. (2007). Gene expression profiles for therapeutic decisions in breast cancer. Revista Médica de Chile, 135 (2), 257-263.
3. Hayes, D., & Thor, A. (2002). c-erbB-2 in breast cancer: development of a clinically useful marker. Seminars in oncology, 29 (3), 231-245.
4. Kumar, V., Abbas, A., & Fausto, N. (2005). Patología Estructural y Funcional (8va ed.) España: Editorial
Elsevier.
5. Slamon, D., Leyland, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., … & Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses
HER2. The New England journal of medicine, 344, 783-792.
6. Harvey, JM., Clark, GM., Osborne, CK., & Allred, DC. (1999). Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of clinical oncology, 17 (5):1474–81.
7. Reis-Filho, J., & Tutt, A. N. (2008). Basal-like breast cancer: a critical review. Histopathology, 52 (1), 108-118.
8. Cleator S, Heller W, Coombes C. Triple negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8: 235–244.
9. Mieog, J., Van der Hage, J., Putter, H., Bartelink, H. Van de Vijver, M., & Van de Velde, C. (2008). Impact of histological grade on prognosis in very young breast cancer patients: pooled analysis of four EORTC trials. European Journal of Cancer Supplements, 6, 194.
10. Brennan, M., French, J., Houssami, N., Kirk, J., & Boyages, J. (2005). Breast Cancer in Young Women. Aust Fam Physician, 34(10), 851-5.
11. Samphao, S., Wheeler, A., Rafferty, E., Michaelson, JS., Specht, MC., … & Smith BL. (2009). Diagnosis of breast cancer in women age 40 and younger: delays in diagnosis result from underuse of genetic testing and breast imaging. Am J Surg, 198, 538- 43.
12. Pollán, M. (2010). Epidemiology of breast cancer in young women. Breast Cancer Res Treat, 126, 3-6.
13. Quirós, J., Jiménez, Y., Jiménez, E., Monge, M., & Salazar, L. (2010). Carcinomas triple negativos de la
glándula mamaria: características clínico-patológicas. Acta Medica Costarricense, 52 (2), 90-95.
14. Quirós, J. Jiménez, I. Ramirez, B.Cáncer de mama en mujeres jóvenes características clínicas y patológicas. Revista Médica de la Universidad de Costa Rica ISSN Impreso: 1659-2441. Volumen 4, Numero 2, (2010).
15. Amadou, A., Torres, G., Hainaut, P., & Romieu, I. (2014). Breast cancer in Latin America: global burden, patterns, and risk factors. Salud Publica Mex, 56, 547-554.
16. Krishnan, S., Madsen, E., Porterfield, D., & Varghese, B. (2013). Advancing cervical cancer prevention in India: Implementation science priorities. The Oncologist, 18, 1285-1297.
17. Brennan, M., French, J., Houssami, N., Kirk, J., & Boyages, J. (2005). Breast Cancer in Young Women. Aust Fam Physician, 34(10), 851-5.
18. Carmichael, A., & Bates, T. (2004). Obesity and breast cancer: a review of the literature. The Breast, 13: 85- 92.
19. Bauer K, Brown M, Cress R, Parise C, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-negative invasive breast cancer, the socalled triple-negative phenotype. Cancer. 2007; 109: 1721-1729.
20. Zhu, W., Perez, E., Hong, R., Li, Q., & Xu, B. (2015). Age-Related Disparity in Immediate Prognosis of
Patients with Triple-Negative Breast Cancer: A Population-Based Study from SEER Cancer Registries. PLoS One, 10(5). doi:10.1371/journal.pone.0128345.
21. Jiménez, G., Villalobos, M., Jiménez, E., & Palma, W. (2007). Determinación de la efectividad de cinco
protocolos de extracción de ADN a partir de material parafinado para estudios moleculares. Rev med UCR, 1, 10-19.
Downloads
Published
Issue
Section
License
The intellectual property of accepted works belongs to their authors, however access to them is totally open and free, so they can be reproduced totally or partially with the only limitation of recognizing the authorship and the source of publication (Revista Medicina Legal de Costa Rica), as long as said exploitation does not have commercial character.
